Exemestane in Post-Menopausal Women With NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Exemestane

One 25 mg tablet once daily for a minimum of 6 weeks

Trial Locations (18)

55072

Essentia Health Sandstone, Sandstone

55362

Monticello Cancer Center (MMCORC), Monticello

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

55731

Fairview Northland Medical Center, Princeton

55744

Fairview Grand Itasca Clinic & Hospital, Grand Rapids

55746

Essentia Health Hibbing, Hibbing

Fairview Range Medical Center, Hibbing

55792

Essentia Health Virginia, Virginia

55805

Essentia Health Cancer Center, Duluth

56001

Mayo Clinic Health System, Mankato

56007

Mayo Clinic Health System, Albert Lea

56187

Sanford Worthington Medical Center, Worthington

56401

Essentia Health St. Joseph's Medical Center, Brainerd

56470

Essentia Health Park Rapids, Park Rapids

56501

Essentia Health St. Mary's Detroit Lakes, Detroit Lakes

56542

Essentia Health Fosston, Fosston

56636

Essentia Health Deer River, Deer River

56701

Sanford Thief River Falls Medical Center, Thief River Falls

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT02666105 - Exemestane in Post-Menopausal Women With NSCLC | Biotech Hunter | Biotech Hunter